The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of defactinib in combination with avutometinib in patients with advanced diffuse-type gastric cancer.
 
Ryan Moy
Consulting or Advisory Role - IDEAYA Biosciences; Nimbus Therapeutics; PureTech
Research Funding - Nimbus Therapeutics; Repare Therapeutics
Travel, Accommodations, Expenses - Nimbus Therapeutics
 
Lawrence Wu
No Relationships to Disclose
 
Hope Cho
No Relationships to Disclose
 
Shikun Wang
No Relationships to Disclose
 
Sarah Sta Ana
No Relationships to Disclose
 
Matthew Strickland
Consulting or Advisory Role - Bristol Myers Squibb; Sedgwick Claims Management
 
Naomi Sender
No Relationships to Disclose
 
Samuel Klempner
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; Eisai; I-Mab; Merck; Novartis; SERVIER; Taiho Oncology
Research Funding - Arcus Biosciences (Inst); BeiGene (Inst); I-Mab (Inst); Leap Therapeutics (Inst); Mersana (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
(OPTIONAL) Uncompensated Relationships - Debbies Dream Foundation; Hope for Stomach Cancer